Raymond James Financial
DSGN icon

Raymond James Financial’s Design Therapeutics DSGN Stock Holding History

Raymond James Financial’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.15M Sell
108,449
-1,314
-1% -$13.3K ﹤0.01% 3753
2025
Q4 		$1.03M Buy
+109,763
New +$859K ﹤0.01% 3753

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Raymond James Financial's DSGN Position: Q1 2026 in Review

Raymond James Financial reduced its Design Therapeutics (DSGN) stake by 1.2% in Q1 2026, selling an estimated $13.3K and leaving 108,449 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3753.

Raymond James Financial first reported a position in DSGN in Q4 2025 and has held it in 2 quarters since. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Raymond James Financial held 108,449 shares of Design Therapeutics worth $1.15M as of Q1 2026.
  • Raymond James Financial sold 1,314 Design Therapeutics shares in Q1 2026, an estimated $13.3K.
  • Design Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3753 holding.
  • Raymond James Financial first reported a position in Design Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.